Caley Castelein
Chairman chez AADI BIOSCIENCE, INC.
Fortune : 24 M $ au 31/03/2024
Profil
Caley M.
Castelein is the founder of KVP Capital LP (founded in 2013), Kearny Venture Partners LP (founded in 2006), and Tourmaline Sub, Inc. (founded in 2022).
Castelein's current jobs include Chairman at Aerpio Therapeutics, Inc. (since 2017), Co-Chairman at Aadi Bioscience, Inc. (since 2021), Director at ViewRay Technologies, Inc. (since 2008), Independent Director at ViewRay, Inc. (since 2008), Director at NewBridge Pharmaceuticals FZ LLC (since 2015), Independent Director at Tourmaline Bio, Inc. (since 2023), and Partner at Kearny Venture Partners.
Castelein's former jobs include Chairman at Aadi Subsidiary, Inc., Director at Waterstone Pharmaceuticals, Inc. (2015-2018), Director at Boreal Genomics, Inc. (2010-2021), Managing Director at Thomas Weisel Partners LLC (2003-2006), Director at Wellpartner LLC (2015-2017), Director at Neos Therapeutics, Inc. (2015), Director at AliveCor, Inc. (2015-2020), Independent Director at Aerpio Pharmaceuticals, Inc., Financial Analyst at Tekla Capital Management LLC, Principal at Calvert Capital Management Co., and General Partner at Thomas Weisel Healthcare Venture Partners LLC.
Castelein holds a doctorate degree from The University of California, San Francisco (conferred in 1999) and an undergraduate degree from Harvard College (conferred in 1993).
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
3,80% | 27/10/2023 | 974 558 ( 3,80% ) | 22 M $ | 31/03/2024 |
AADI BIOSCIENCES, INC.
2,12% | 15/06/2023 | 519 692 ( 2,12% ) | 1 M $ | 31/03/2024 |
VIEWRAY, INC.
0,05% | 19/07/2023 | 99 047 ( 0,05% ) | - $ | 29/02/2024 |
Postes actifs de Caley Castelein
Sociétés | Poste | Début |
---|---|---|
VIEWRAY, INC. | Director/Board Member | 01/01/2008 |
AADI BIOSCIENCE, INC. | Chairman | 26/08/2021 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Founder | 01/09/2022 |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | Director/Board Member | 01/03/2015 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Chairman | - |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | Director/Board Member | 01/01/2008 |
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | Private Equity Investor | - |
Anciens postes connus de Caley Castelein
Sociétés | Poste | Fin |
---|---|---|
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Chairman | 01/01/2023 |
Boreal Genomics, Inc.
Boreal Genomics, Inc. Medical SpecialtiesHealth Technology Boreal Genomics, Inc. develops and markets DNA and RNA purification, enrichment, and detection equipment and tools. It provides research tools and developing diagnostic tests based on non invasive tumor profiling and monitoring of cancer. The company’s OnTarget platform performs sensitive genomic analysis of cell free DNA in plasma to detect and quantify mutations in tumor derived circulating nucleic acids. The company was founded by Andre Marziali, Jason Donald Thompson, Joel Pel and David J. Broemeling in 2007 and is headquartered in Vancouver, Canada. | Director/Board Member | 01/09/2021 |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Caley Castelein
The University of California, San Francisco | Doctorate Degree |
Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
VIEWRAY, INC. | Health Technology |
AADI BIOSCIENCE, INC. | Health Technology |
Entreprise privées | 18 |
---|---|
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | Commercial Services |
Kearny Venture Partners LP
Kearny Venture Partners LP Investment ManagersFinance Kearny Venture Partners LP invests in US healthcare companies operating in the fields of medical devices and drugs (small molecules & biopharmaceuticals). The fund invests in the range of $10 - $15 million per company with an initial investment of $2 - $8 million. It provides financing for seed, early & later-stage capital requirements. | Finance |
Waterstone Pharmaceuticals, Inc.
Waterstone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Waterstone Pharmaceuticals, Inc. engages in the provision of discovery, development, and commercialization of innovative drugs for the treatment of liver and gastrointestinal diseases. The company was founded by Faming Zhang in 2008 and is headquartered in Carmel, IN. | Health Technology |
Boreal Genomics, Inc.
Boreal Genomics, Inc. Medical SpecialtiesHealth Technology Boreal Genomics, Inc. develops and markets DNA and RNA purification, enrichment, and detection equipment and tools. It provides research tools and developing diagnostic tests based on non invasive tumor profiling and monitoring of cancer. The company’s OnTarget platform performs sensitive genomic analysis of cell free DNA in plasma to detect and quantify mutations in tumor derived circulating nucleic acids. The company was founded by Andre Marziali, Jason Donald Thompson, Joel Pel and David J. Broemeling in 2007 and is headquartered in Vancouver, Canada. | Health Technology |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
KVP Capital LP | Miscellaneous |
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. | Finance |
Thomas Weisel Partners LLC
Thomas Weisel Partners LLC Investment Banks/BrokersFinance Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare. | Finance |
Wellpartner LLC
Wellpartner LLC Medical DistributorsDistribution Services Wellpartner LLC engages in the provision of pharmacy services. It offers 340B program management. It provides a seamless, easy-to-use solution for covered entities currently or considering participating in the 340B Drug Program. The company was founded by Michael W. Wright and Robert Judge in November 1998 and is headquartered in Tualatin, OR. | Distribution Services |
Calvert Capital Management Co.
Calvert Capital Management Co. Investment ManagersFinance Calvert Capital Management Co. (Calvert Capital Management) is a venture capital firm founded in 1982. The firm is headquartered in Waltham, Massachusetts. | Finance |
Neos Therapeutics, Inc.
Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
Thomas Weisel Healthcare Venture Partners LLC
Thomas Weisel Healthcare Venture Partners LLC Investment ManagersFinance Thomas Weisel Healthcare Venture Partners LLC (Thomas Weisel Healthcare) is an Independent Private Equity firm founded in 2001. The firm is headquartered in San Francisco. | Finance |
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | Finance |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | Health Technology |
AliveCor, Inc.
AliveCor, Inc. Packaged SoftwareTechnology Services AliveCor, Inc. develops mobile heart monitoring system. It offers kardia mobile that provides people with suspected or diagnosed heart conditions, and those at risk of heart conditions. The company was founded by David E. Albert, Bruce Satchwell, and Kim Barnett and is headquartered in San Francisco, CA. | Technology Services |
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Health Technology |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The private company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |